Acute Coronary SyndromesRENASCA-IMSSNCT02255344
Multicenter Study to Develop a Risk Model for Early Major Cardiovascular Events
An observational study of Acute Coronary Syndromes, run by Instituto Mexicano del Seguro Social at 1 site in Mexico.
Trial summary
Through the National Registry of patients with ACS in the IMSS (RENASCA IMSS) the investigators will know the real world in terms of risk factors frequency, clinical presentation and its complications, and in the end they can build a risk model for early Major Cardiovascular Events (MACE). Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Acute Coronary Syndromes
- How many people
- 21,827 participants
- Where
- 1 siteMexico
- Study dates
- Aug 2014to Feb 2020
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Consecutive patients of any gender between 18 and 90 years old, diagnosed with Acute Coronary Syndrome (STEMI/ NSTEMI/ Unstable angina - according to international diagnostic criteria - ACC / AHA / ESC), attended in representative hospitals of tertiary care in the IMSS will be studied.
Who may be able to join
- Consecutive patients of any gender between 18 and 90 years old
- Diagnosed with Acute Coronary Syndrome (STEMI/ NSTEMI/ Unstable angina - according to international diagnostic criteria - ACC / AHA / ESC)
Who cannot join
- Cardiomyopathies
- Congenital Disease
- Acute Pulmonary Embolism
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Multicenter Study to Develop a Risk Model for Early Major Cardiovascular Events Based on the IMSS National Registry of Acute Coronary Syndromes (RENASCA IMSS). Stage 1
Through the National Registry of patients with ACS in the IMSS (RENASCA IMSS) the investigators will know the real world in terms of risk factors frequency, clinical presentation and its complications, and in the end they can build a risk model for early Major Cardiovascular Events (MACE).
Read the detailed description
Introduction: Ischemic heart diseases as the leading cause of death in Mexico are mainly due to acute myocardial infarction. In this sense, reperfusion strategies are the cornerstone of treatment to reduce complications and costs; however, less than 50 percent of patients receive this treatment as a third of the world's population dies by this cause.
The World Health Organization (WHO) predicts for the next two decades about 23.5 million deaths worldwide by cardiovascular diseases. Particularly Acute Coronary Syndrome (ACS) caused in 2008 about seven million deaths worldwide. It is estimated that each year in Mexico around 300 thousand people suffer an ACS, at least 60 percent of these is caused by Myocardial Infarction (MI) but there are not real numbers for morbidity nor real clinical complications.
Efforts have been made in Mexican registries of ACS as shown in the first real world study done in the IMSS which serves the greater number of these cases (54.4 percent) called "National Registry of Acute Coronary Syndromes" (RENASCA IMSS). In this registry 10 tertiary care hospitals participated enrolling 2,398 patients with ACS diagnosis, most of them with ST-Elevation Myocardial Infarction (STEMI), representing 63 percent; the average age was 62 years. In 65 percent of cases stratified as high risk (GRACE> 150 points), only 42 percent were treated with fibrinolytic therapy, 8 percent with primary Percutaneous Coronary Intervention (PCI) and the remaining 50 percent did not receive any reperfusion therapy which is the cornerstone for the prognosis of these patients.
Currently Mexico is experiencing an increase in the elderly population and in the frequency of traditional risk factors for atherosclerosis associated with factors such as overweight and obesity which has become a high-risk population group for ischemic heart diseases and its complications. It represents a challenge to the health system from the point of view of prevention in the beginning but also in the diagnosis, prognosis, and treatment.
Treatment goals in traditional risk factors have not been accomplished yet. Patients are diagnosed late and there is not a risk model in our population since more than 50 percent of patients do not receive adequate treatment.
Therefore it is necessary to have a current outlook of what is happening in the mexican population through a National Registry of patients with ACS in the IMSS (RENASCA IMSS). This will allow to know the real world in terms of risk factors frequency, clinical presentation and its complications, and in the end a risk model can be built.
OBJECTIVE: To develop a risk model for early Major Cardiovascular Events (MACE) in patients with Acute Coronary Syndrome (ACS) based on the IMSS National Registry of Acute Coronary Syndromes (RENASCA IMSS.)
MATERIAL AND METHODS: Consecutive patients of any gender between 18 and 90 years old, diagnosed with Acute Coronary Syndrome (STEMI/ NSTEMI/ Unstable angina - according to international diagnostic criteria - American College of Cardiology (ACC) / American Heart Association (AHA) / European society of Cardiology (ESC), attended in representative hospitals of tertiary care in the IMSS will be studied.
The design is an analytical consecutive prospective multicenter study with an emerging cohort of patients with ACS through a National Registry in units of tertiary care in the IMSS (RENASCA IMSS). Follow-up will be done during hospitalization and 30 days, time of most Major Cardiovascular Events presentation (MACE) derived from the timing of initial treatment or lack of it.
MACE to evaluate during Follow-up will be: Reinfarction, myocardial ischemia, heart failure, electrocardiographic complications and / or death (mortality). 8 tertiary care hospitals or Medical Units of High Specialty (UMAES for its acronym in Spanish) will participated representing the country: an analysis of clinical and paraclinical variables contained in the record considered as relevant in predicting the inception cohort for MACE during hospitalization and 30 days will be done. The cohort of major cardiovascular events (as previously defined) will be compared with the cohort comprised by patients without such events.
Statistical analysis will be done with central tendency and dispersion measures according to the distribution of the variables. We will use the hypothesis testing according to the normality of data with T-test for independent groups or Mann-Whitney test for continuous variables, whereas for categorical variables X2 test or Fisher exact test when the observed frequency is <5 will be used. The free event will be analyzed with Kaplan Meier curves. To determine the correlation of performers (blind and independent) of angiography and echocardiography we will use the Kappa index.
The development of the risk model will be performed with logistic regression which dependent variable is the presence of MACE during hospitalization and 30 days (Wald method, backward). Variables for clinical and epidemiological history considered as relevant will be included, according also with the biological and epidemiological consistency and plausibility. The statistical criteria will be the inclusion of variables that in the bivariate analysis show p <0.20 and the exit criteria of the model will be p≥0.05.
The discriminative power of the model will be done with the area under the Receiver Operating Characteristic curve (ROC curve). The calibration will be done with the Hosmer-Lemeshow test. Relative risk with confidence intervals of 95 percent will be calculated. All hypothesis tests will be done under an alpha level of <0.05.
TIME OF DEVELOPMENT: Two years.
- Conditions
- Acute Coronary Syndromes
- Keywords
- Acute Coronary Syndromes, Risk Model, National Registry, Comprehensive Care Program, Major Cardiovascular Events
- Medical subject headings
- Acute Coronary Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| ST-Elevation Myocardial Infarction | Consecutive patients of any gender between 18 and 90 years old, diagnosed with ST-Elevation Myocardial Infarction according to international diagnostic criteria - ACC / AHA / ESC, attended in representative hospitals of tertiary and secondary care in the IMSS will be studied | |
| Non ST Segment Elevation | Consecutive patients of any gender between 18 and 90 years old, diagnosed with Non ST Segment Elevation (NSTEMI/ Unstable angina) according to international diagnostic criteria - ACC / AHA / ESC, attended in representative hospitals of tertiary and secondary care in the IMSS will be studied |
What is being measured
The primary outcome is the main question the study is designed to answer.
Major Cardiovascular Events (MACE)
Follow-up will be done during hospitalization and 30 days, time of most Major Cardiovascular Events presentation (MACE: Reinfarction, myocardial ischemia, heart failure, electrocardiographic complications and / or death ) derived from the timing of initial treatment or lack of it
Measured: up to 1 year
Secondary outcomes (1)
medical care cost in Instituto Mexicano del Seguro Social
Measured: 30 days and 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Oct 2014 (estimated)
- Study startAug 2014
- Primary completionDec 2019
- Study completionFeb 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Coronary SyndromesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 21,827 participants (actual)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- Instituto Mexicano del Seguro Social
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Gabriela Borrayo Sanchez, Instituto Mexicano del Seguro Social
- Investigators
- Gabriela Borrayo, MD, Principal investigator, Instituto Mexicano del Seguro Social
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02255344
- Sponsor's protocol ID
- R-2014-785-051
- Acronym
- RENASCA-IMSS
- Status last verified
- Feb 2020
- First submitted
- 25 Sep 2014
- Last updated
- 11 Feb 2020
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Feb 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multicenter Study to Develop a Risk Model for Early Major Cardiovascular Events Based on the IMSS National Registry of Acute Coronary Syndromes (RENASCA IMSS). Stage 1
- ClinicalTrials.gov ID
- NCT02255344
- Acronym / sponsor ID
- RENASCA-IMSS / R-2014-785-051
- Conditions
- Acute Coronary Syndromes
- Keywords
- Acute Coronary Syndromes, Risk Model, National Registry, Comprehensive Care Program, Major Cardiovascular Events
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 21,827 participants (actual)
- Lead sponsor
- Instituto Mexicano del Seguro SocialOther government
- Study start
- Aug 2014 (actual)
- Primary completion
- Dec 2019 (actual)
- Study completion
- Feb 2020 (actual)
- First posted
- 2 Oct 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Through the National Registry of patients with ACS in the IMSS (RENASCA IMSS) the investigators will know the real world in terms of risk factors frequency, clinical presentation and its complications, and in the end they can build a risk model for early Major Cardiovascular Events (MACE).
Detailed description
Introduction: Ischemic heart diseases as the leading cause of death in Mexico are mainly due to acute myocardial infarction. In this sense, reperfusion strategies are the cornerstone of treatment to reduce complications and costs; however, less than 50 percent of patients receive this treatment as a third of the world's population dies by this cause.
The World Health Organization (WHO) predicts for the next two decades about 23.5 million deaths worldwide by cardiovascular diseases. Particularly Acute Coronary Syndrome (ACS) caused in 2008 about seven million deaths worldwide. It is estimated that each year in Mexico around 300 thousand people suffer an ACS, at least 60 percent of these is caused by Myocardial Infarction (MI) but there are not real numbers for morbidity nor real clinical complications.
Efforts have been made in Mexican registries of ACS as shown in the first real world study done in the IMSS which serves the greater number of these cases (54.4 percent) called "National Registry of Acute Coronary Syndromes" (RENASCA IMSS). In this registry 10 tertiary care hospitals participated enrolling 2,398 patients with ACS diagnosis, most of them with ST-Elevation Myocardial Infarction (STEMI), representing 63 percent; the average age was 62 years. In 65 percent of cases stratified as high risk (GRACE> 150 points), only 42 percent were treated with fibrinolytic therapy, 8 percent with primary Percutaneous Coronary Intervention (PCI) and the remaining 50 percent did not receive any reperfusion therapy which is the cornerstone for the prognosis of these patients.
Currently Mexico is experiencing an increase in the elderly population and in the frequency of traditional risk factors for atherosclerosis associated with factors such as overweight and obesity which has become a high-risk population group for ischemic heart diseases and its complications. It represents a challenge to the health system from the point of view of prevention in the beginning but also in the diagnosis, prognosis, and treatment.
Treatment goals in traditional risk factors have not been accomplished yet. Patients are diagnosed late and there is not a risk model in our population since more than 50 percent of patients do not receive adequate treatment.
Therefore it is necessary to have a current outlook of what is happening in the mexican population through a National Registry of patients with ACS in the IMSS (RENASCA IMSS). This will allow to know the real world in terms of risk factors frequency, clinical presentation and its complications, and in the end a risk model can be built.
OBJECTIVE: To develop a risk model for early Major Cardiovascular Events (MACE) in patients with Acute Coronary Syndrome (ACS) based on the IMSS National Registry of Acute Coronary Syndromes (RENASCA IMSS.)
MATERIAL AND METHODS: Consecutive patients of any gender between 18 and 90 years old, diagnosed with Acute Coronary Syndrome (STEMI/ NSTEMI/ Unstable angina - according to international diagnostic criteria - American College of Cardiology (ACC) / American Heart Association (AHA) / European society of Cardiology (ESC), attended in representative hospitals of tertiary care in the IMSS will be studied.
The design is an analytical consecutive prospective multicenter study with an emerging cohort of patients with ACS through a National Registry in units of tertiary care in the IMSS (RENASCA IMSS). Follow-up will be done during hospitalization and 30 days, time of most Major Cardiovascular Events presentation (MACE) derived from the timing of initial treatment or lack of it.
MACE to evaluate during Follow-up will be: Reinfarction, myocardial ischemia, heart failure, electrocardiographic complications and / or death (mortality). 8 tertiary care hospitals or Medical Units of High Specialty (UMAES for its acronym in Spanish) will participated representing the country: an analysis of clinical and paraclinical variables contained in the record considered as relevant in predicting the inception cohort for MACE during hospitalization and 30 days will be done. The cohort of major cardiovascular events (as previously defined) will be compared with the cohort comprised by patients without such events.
Statistical analysis will be done with central tendency and dispersion measures according to the distribution of the variables. We will use the hypothesis testing according to the normality of data with T-test for independent groups or Mann-Whitney test for continuous variables, whereas for categorical variables X2 test or Fisher exact test when the observed frequency is <5 will be used. The free event will be analyzed with Kaplan Meier curves. To determine the correlation of performers (blind and independent) of angiography and echocardiography we will use the Kappa index.
The development of the risk model will be performed with logistic regression which dependent variable is the presence of MACE during hospitalization and 30 days (Wald method, backward). Variables for clinical and epidemiological history considered as relevant will be included, according also with the biological and epidemiological consistency and plausibility. The statistical criteria will be the inclusion of variables that in the bivariate analysis show p <0.20 and the exit criteria of the model will be p≥0.05.
The discriminative power of the model will be done with the area under the Receiver Operating Characteristic curve (ROC curve). The calibration will be done with the Hosmer-Lemeshow test. Relative risk with confidence intervals of 95 percent will be calculated. All hypothesis tests will be done under an alpha level of <0.05.
TIME OF DEVELOPMENT: Two years.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 2 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ST-Elevation Myocardial Infarction | – | –Consecutive patients of any gender between 18 and 90 years old, diagnosed with ST-Elevation Myocardial Infarction according to international diagnostic criteria - ACC / AHA / ESC, attended in representative hospitals of tertiary and secondary care in the IMSS will be studied |
| Non ST Segment Elevation | – | –Consecutive patients of any gender between 18 and 90 years old, diagnosed with Non ST Segment Elevation (NSTEMI/ Unstable angina) according to international diagnostic criteria - ACC / AHA / ESC, attended in representative hospitals of tertiary and secondary care in the IMSS will be studied |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Consecutive patients of any gender between 18 and 90 years old, diagnosed with Acute Coronary Syndrome (STEMI/ NSTEMI/ Unstable angina - according to international diagnostic criteria - ACC / AHA / ESC), attended in representative hospitals of tertiary care in the IMSS will be studied.
Key inclusion criteria (2 listed)
- Consecutive patients of any gender between 18 and 90 years old
- Diagnosed with Acute Coronary Syndrome (STEMI/ NSTEMI/ Unstable angina - according to international diagnostic criteria - ACC / AHA / ESC)
Key exclusion criteria (3 listed)
- Cardiomyopathies
- Congenital Disease
- Acute Pulmonary Embolism
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Major Cardiovascular Events (MACE)
Time frame: up to 1 year
Follow-up will be done during hospitalization and 30 days, time of most Major Cardiovascular Events presentation (MACE: Reinfarction, myocardial ischemia, heart failure, electrocardiographic complications and / or death ) derived from the timing of initial treatment or lack of it
1 secondary outcome
medical care cost in Instituto Mexicano del Seguro Social
Time frame: 30 days and 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Feb 2020.
Related trials for Acute Coronary Syndromes
Not yet recruitingPhase 4
Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia
Acute Coronary Syndrome
Not yet recruitingPhase 3
Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis
Giant Cell Arteritis (GCA), Acute Coronary Syndrome (ACS)
Recruiting
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study
Coronary Arterial Disease (CAD), Plaque
RecruitingPhase 4
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome
ACS (Acute Coronary Syndrome), SGLT2 Inhibitors
Enrolling by invitation
Optical Coherence Tomography in Acute Vessel Evaluation
Ischemic Heart Disease, Ischemic Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gabriela Borrayo, MD principal investigator
Instituto Mexicano del Seguro Social
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Coronary Syndromes, run by Instituto Mexicano del Seguro Social at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Major Cardiovascular Events (MACE) (time frame: up to 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2020.